NCT06467370Completed
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
CONFIDENCE: A PROSPECTIVE OBSERVATIONAL STUDY WITH ACUTE TREATMENT OF RIMEGEPANT ODT ON CONSISTENCY, SATISFACTION AND TOLERABILITY OF TREATMENT IN THE REAL WORLD
Source: ClinicalTrials.gov · Last updated 30 Jun 2026
Brief summary (registry, in English)
This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely monoclonal antibodies targeting CGRP and onabotulinumtoxinA
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 467 (actual)
- First submitted
- 14 Jun 2024
- Start date
- 2 Jul 2024
- Primary completion date
- 11 Mar 2025
- Lead sponsor
- Pfizer
- Diseases
- Migraine
- NCT number
- NCT06467370
What you commit to
- Study type: Observational
- Participants enrolled: 467
- From 2 Jul 2024 to the primary completion date, 11 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Report currently using rimegepant as preventive
- Report currently using concomitantly onabotulinumtoxin and any of the mAbs
Other
- Currently participating in a Migraine-related clinical trial
- Reports a diagnosis from a doctor or other health professional of cluster headache, post-traumatic headache, new daily persistent headache, or hemicrania continua
Who the study is looking for
- Female or male patients with migraine ≥18 years old
- Having received a prescription for rimegepant for acute treatment
- Experienced between 3 and 14 Headache days in the last 30 days
- Planning to use rimegepant for attacks happening during the next 30 days
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | New York | United States | Unknown status |
Related publications
- Effectiveness of Rimegepant for the Acute Treatment of Migraine Among Participants Using Different Types of Preventive Therapy: Analyses from CONFIDENCE.Neurol Ther · 2026 · PMID 42717153
- Consistency of response to rimegepant for the acute treatment of migraine among real-world users - findings from the prospective observational CONFIDENCE study.J Headache Pain · 2026 · PMID 42286469
This page is information, not medical advice. Discuss any trial with your doctor.